SIRT and Peri-immunotherapy : a New Concept

Condition(s) studied

Investigational drug(s) / intervention(s)

Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization: Atezolizumab ± Bevacizumab: Peri-immunotherapy with , with or without bevacizumab, given before and after SIRT. \- Yttrium-90 Radioembolization: Selective Internal Radiation Therapy (SIRT) via intra-arterial injection of Yttrium-90 microspheres for liver tumor control

Atezolizumab ± Bevacizumab: Standard systemic immunotherapy administered without SIRT, using atezolizumab with or without bevacizumab.

Study summary

The combination of selective internal radiation therapy (SIRT) with immunotherapy represents an innovative and potentially highly effective therapeutic strategy for the treatment of advanced-stage hepatocellular carcinoma (BCLC stage B or C). Although promising results have been observed in preliminary clinical trials, further research is needed to better understand the underlying mechanisms, optimize treatment protocols, and confirm the long-term efficacy and safety of this combined approach

Eligibility

Primary outcome measure(s)

• Objective Tumor Response Rate — At 3, 6, 9 and 12 months post-treatment
  Proportion of patients achieving complete or partial response, evaluated by CT or MRI using RECIST 1.1, mRECIST, iRECIST, and LI-RADS therapeutic criteria

Trial sites (1)

More Assistance Publique - Hôpitaux de Paris trials in France